KOPS - Das Institutionelle Repositorium der Universität Konstanz

Conversion of CD95 (Fas) Type II into Type I signaling by sub-lethal doses of cycloheximide

Conversion of CD95 (Fas) Type II into Type I signaling by sub-lethal doses of cycloheximide

Zitieren

Dateien zu dieser Ressource

Prüfsumme: MD5:034c3d830fb006e8f02a7b0ab34e2ae5

BRUMATTI, Gabriela, Monica YON, Fabiola A. CASTRO, Ana Elisa Barreiros BUENO-DA-SILVA, Jacqueline F. JACYSYN, Thomas BRUNNER, Gustavo P. AMARANTE-MENDES, 2008. Conversion of CD95 (Fas) Type II into Type I signaling by sub-lethal doses of cycloheximide. In: Experimental Cell Research. 314(3), pp. 554-563. ISSN 0014-4827. Available under: doi: 10.1016/j.yexcr.2007.11.003

@article{Brumatti2008-02-01Conve-14270, title={Conversion of CD95 (Fas) Type II into Type I signaling by sub-lethal doses of cycloheximide}, year={2008}, doi={10.1016/j.yexcr.2007.11.003}, number={3}, volume={314}, issn={0014-4827}, journal={Experimental Cell Research}, pages={554--563}, author={Brumatti, Gabriela and Yon, Monica and Castro, Fabiola A. and Bueno-da-Silva, Ana Elisa Barreiros and Jacysyn, Jacqueline F. and Brunner, Thomas and Amarante-Mendes, Gustavo P.} }

<rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bibo="http://purl.org/ontology/bibo/" xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:void="http://rdfs.org/ns/void#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > <rdf:Description rdf:about="https://kops.uni-konstanz.de/rdf/resource/123456789/14270"> <dc:creator>Bueno-da-Silva, Ana Elisa Barreiros</dc:creator> <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2011-10-19T13:33:15Z</dc:date> <dc:contributor>Bueno-da-Silva, Ana Elisa Barreiros</dc:contributor> <dc:creator>Brunner, Thomas</dc:creator> <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/rdf/resource/123456789/28"/> <dc:creator>Yon, Monica</dc:creator> <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/14270/2/2007_Brumatti_conversion.pdf"/> <dc:contributor>Brunner, Thomas</dc:contributor> <dc:creator>Amarante-Mendes, Gustavo P.</dc:creator> <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2011-10-19T13:33:15Z</dcterms:available> <dc:creator>Castro, Fabiola A.</dc:creator> <dc:contributor>Castro, Fabiola A.</dc:contributor> <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/> <dc:language>eng</dc:language> <dc:creator>Brumatti, Gabriela</dc:creator> <dcterms:title>Conversion of CD95 (Fas) Type II into Type I signaling by sub-lethal doses of cycloheximide</dcterms:title> <dc:contributor>Jacysyn, Jacqueline F.</dc:contributor> <dcterms:bibliographicCitation>First publ. in: Experimental Cell Research ; 314 (2008), 3. - pp. 554-563</dcterms:bibliographicCitation> <bibo:uri rdf:resource="http://kops.uni-konstanz.de/handle/123456789/14270"/> <dc:contributor>Yon, Monica</dc:contributor> <dc:contributor>Amarante-Mendes, Gustavo P.</dc:contributor> <dc:contributor>Brumatti, Gabriela</dc:contributor> <foaf:homepage rdf:resource="http://localhost:8080/jspui"/> <dcterms:abstract xml:lang="eng">CD95 (Fas/Apo-1)-mediated apoptosis was shown to occur through two distinct pathways. One involves a direct activation of caspase-3 by large amounts of caspase-8 generated at the DISC (Type I cells). The other is related to the cleavage of Bid by low concentration of caspase-8, leading to the release of cytochrome c from mitochondria and the activation of caspase-3 by the cytochrome c/APAF-1/caspase-9 apoptosome (Type II cells). It is also known that the protein synthesis inhibitor cycloheximide (CHX) sensitizes Type I cells to CD95-mediated apoptosis, but it remains contradictory whether this effect also occurs in Type II cells. Here, we show that sub-lethal doses of CHX render both Type I and Type II cells sensitive to the apoptogenic effect of anti-CD95 antibodies but not to chemotherapeutic drugs. Moreover, Bcl-2-positive Type II cells become strongly sensitive to CD95-mediated apoptosis by the addition of CHX to the cell culture. This is not the result of a restraint of the anti-apoptotic effect of Bcl-2 at the mitochondrial level since CHX-treated Type II cells still retain their resistance to chemotherapeutic drugs. Therefore, CHX treatment is granting the CD95-mediated pathway the ability to bypass the mitochondria requirement to apoptosis, much alike to what is observed in Type I cells.</dcterms:abstract> <dcterms:issued>2008-02-01</dcterms:issued> <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/14270/2/2007_Brumatti_conversion.pdf"/> <dc:creator>Jacysyn, Jacqueline F.</dc:creator> <dc:rights>deposit-license</dc:rights> <dcterms:rights rdf:resource="http://nbn-resolving.org/urn:nbn:de:bsz:352-20140905103605204-4002607-1"/> <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/rdf/resource/123456789/28"/> </rdf:Description> </rdf:RDF>

Dateiabrufe seit 01.10.2014 (Informationen über die Zugriffsstatistik)

2007_Brumatti_conversion.pdf 189

Das Dokument erscheint in:

KOPS Suche


Stöbern

Mein Benutzerkonto